Oncology Reimbursement Changes Could Close Small Practices, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive SummaryAmgen remains confident its oncology portfolio is on track to deliver growth despite changes in reimbursement in the market, Associate Director-Investor Relations Laura Biswas said
You may also be interested in...
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.